Physician profile
Marjorie Ramos
NPI 1982736567
$273.62
in general payments reported to CMS, 2019-2025
2 companies · $75.61 in 2025
The $75.61 reported for 2025 was less than what a typical General Practice (Dentist) provider received nationally (typical 2025 total: $74.60).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.00 · 2023: $59.94 · 2024: $82.07 · 2025: $75.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143 · Consulting Fee: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.62 |
| Consulting Fee | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Align Technology, INC. | $213.68 | 2021-2025 | Invisalign |
| Straumann USA LLC | $59.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.